Skip to content
- Appraise the current role of systemic therapy in nonmetastatic prostate carcinoma (PC)
- Select novel therapies for newly diagnosed metastatic PC
- Evaluate the role of immunotherapy options with check point inhibitors in PC
- Apply multitargeted kinase inhibitor, lenvatib in the treatment of metastatic renal cell carcinoma (RCC)
- Examine optimal therapy with MET, AXL and VEGF receptor Inhibitor, canozantinib in the treatment of metastatic RCC
- Assess the immunotherapy options with novel PD-1/PD-L1 checkpoint inhibitors and targeted therapy combinations in patients with RCC
- Review the genetic alterations in the molecular subtypes of urothelial bladder cancer (UBC)
- Appraise the efficacy and safety of novel immunotherapy approaches with PD-1/PD-L1 antibodies in patients with UBC
